Homology Medicines

Albert Seymour, Ph.D., President and CEO 

Oct. 11 | 3:15pm | UBC Ballroom 

Bedford, MA 


In-person Presentation 

Homology Medicines is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. Homology’s clinical programs include HMI-102, an investigational gene therapy for adults with PKU; HMI-103, a gene editing candidate for PKU; and HMI-203, an investigational gene therapy for Hunter syndrome. Additional programs focus on metachromatic leukodystrophy, paroxysmal nocturnal hemoglobinuria, and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus vectors to precisely and efficiently deliver genetic medicines in vivo through a gene therapy or nuclease-free gene editing modality, as well as to deliver one-time gene therapy to produce antibodies throughout the body through the GTx-mAb platform. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise, and broad intellectual property position the company as a leader in genetic medicines. 


By using this website you agree to accept our Privacy Policy and Terms & Conditions